After disastrous Galapagos deal, Gilead finds new rheumatoid arthritis partner

Gilead is look­ing for an­oth­er shot at treat­ing rheuma­toid arthri­tis af­ter its mas­sive Gala­pa­gos deal fell flat in the face of an FDA re­jec­tion and, more re­cent­ly, a with­drawn Phase I of an­oth­er as­set for the in­flam­ma­to­ry dis­ease. The Cal­i­for­nia bio­phar­ma, com­ing off a…#gilead #gs5718 #nanodisc #googles #finish #danieloday #massivegalapagos #irak4 #evoq #disease
Source: Reuters: Health - Category: Consumer Health News Source Type: news